Employees: 1,304
Size Japan Lifeline (7575.T) is a Japan Health Care company (Medical Specialties) with a market value of $703M, the 911th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,713 on 18 Nov 2026.
Performance Over six months the shares gained 33.7%, against -15.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 5.8% over the last twelve months (peer median +14.8%); the operating margin is 18.7% (peer median 10.6%).
Valuation It trades at 14.5× forward earnings against a peer median of 23.2× (4th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥61.3B | ¥59.2B | ¥56.6B | ¥51.4B | ¥51.8B |
| Revenue growth | — | +5% | +10% | -1% | — |
| Gross profit | ¥35.6B | ¥34.5B | ¥33.1B | ¥30.4B | ¥29.0B |
| EBITDA | ¥13.1B | ¥14.4B | ¥14.6B | ¥12.8B | ¥12.7B |
| Net income | ¥9.01B | ¥9.35B | ¥9.32B | ¥7.51B | ¥6.89B |
| Free cash flow | n/a | ¥6.27B | ¥7.56B | ¥4.79B | ¥10.7B |
| Capital expenditure | n/a | ¥1.97B | ¥1.99B | ¥2.34B | ¥1.73B |
| Total debt | ¥3.58B | ¥3.12B | ¥3.97B | ¥4.63B | ¥6.88B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7575.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.9% | -8.9% | 3rd highest of 21 |
| 6-month return | +33.7% | -15.1% | 4th highest of 21 |
| Distance from 52-week high | -1.2% | -38.3% | highest of 21 |
| Revenue growth (TTM) | +5.8% | +14.8% | 7th lowest of 21 |
| Operating margin | 18.7% | 10.6% | 5th highest of 21 |
| Forward P/E | 14.5× | 23.2× | 4th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -9.5% | 10.1% | 2nd least demanding of 16 |
| Growth delivered (Del g) | +2.9% | +14.2% | 4th lowest of 16 |
| Hurdle (Req g minus delivered) | -12.4 pp | -9.8 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +8.6 pp | +2.3 pp | 7th highest of 21 |
| EV / EBITDA | 7.9× | 11.1× | 2nd cheapest of 6 |
| Net debt / EBITDA | -0.6× | -1.7× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Japan Lifeline 7575.T | Japan | $703M | +34% | +6% | 19% | 14.5× | -9.5% | +2.9% |
| SWS Hemodialysis Care 688410.SS | China | $706M | -11% | +31% | 19% | 23.5× | 16.2% | +25.9% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $700M | -25% | +35% | 21% | 15.9× | -3.3% | +23.5% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $697M | +148% | -14% | 3% | n/a | 31.8% | -0.6% |
| Doctorglasses Chain 300622.SZ | China | $710M | -22% | +6% | 14% | 22.8× | -3.4% | +15.7% |
| Shanghai Sanyou Medical 688085.SS | China | $692M | -23% | +15% | 4% | 50.0× | 29.0% | +6.8% |
| Shenzhen Lifotronic Technology 688389.SS | China | $692M | -14% | +14% | 13% | 29.9× | 11.6% | +13.3% |
| Livsmed 491000.KS | South Korea | $687M | -47% | +89% | -77% | n/a | n/a | n/a |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 55.4× | n/a | n/a |
| Delcath Systems DCTH | United States | $685M | +75% | +38% | 5% | 358.9× | 33.4% | +120.2% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $680M | -9% | +29% | 5% | 39.0× | 10.1% | +14.2% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |
| Shanghai Kinetic Medical 300326.SZ | China | $662M | -10% | -28% | 17% | 26.0× | 6.6% | -1.9% |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 13.8× | 0.2% | +47.5% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | n/a | n/a | n/a |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 10.7× | n/a | n/a |